<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autoimmune hemolytic anemia (AIHA) in children: Classification, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Russell E Ware, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sarah O'Brien, MD, MSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Autoimmune hemolytic anemia (AIHA) is a collection of disorders characterized by the presence of autoantibodies that bind to the patient's own erythrocytes, leading to premature red cell destruction (hemolysis) and, when the rate of hemolysis exceeds the ability of the bone marrow to replace the destroyed red cells, to anemia and its attendant signs and symptoms.</p><p>The classification, clinical presentation, and diagnosis of AIHA in children are reviewed here. A general overview of childhood hemolytic anemias is presented separately, as are other aspects related to AIHA, including pathophysiology, treatment, and prognosis of AIHA, and diagnosis and management of paroxysmal cold hemoglobinuria (PCH):</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/107301.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Pathogenesis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Pathogenesis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria"</a>.)</p><p></p><p class="headingAnchor" id="H2421059475"><span class="h1">CLASSIFICATION</span></p><p class="headingAnchor" id="H164676771"><span class="h2">Warm and cold agglutinins</span><span class="headingEndMark"> — </span>AIHA is generally categorized as "warm" or "cold" based on the thermal reactivity of the autoantibodies (ie, the optimal temperature at which the antibodies bind to erythrocytes)  (<a class="graphic graphic_table graphicRef55710" href="/d/graphic/55710.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warm-reactive AIHA</strong> – The most common form of primary AIHA in children, accounting for 60 to 90 percent of cases, involves warm-reactive autoantibodies, usually immunoglobulin G (IgG), that bind preferentially to the red cells at 37°C, leading to extravascular hemolysis mainly in the spleen, with resulting anemia, jaundice and, occasionally, splenomegaly. In some cases, IgG is present in sufficient quantity and proximity to fix complement, resulting in features of concomitant intravascular hemolysis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cold agglutinin disease</strong> – Cold agglutinin disease is relatively uncommon in children, amounting to approximately 10 percent of cases, most commonly occurring after <em>Mycoplasma</em> <em>pneumoniae</em> or Epstein-Barr virus infection. In this disorder, immunoglobulin M (IgM) autoantibodies bind erythrocyte I/i or, rarely, anti-PR antigens at colder temperatures and fix complement, which leads to anemia, either due to complement-mediated intravascular hemolysis or immune-mediated extravascular clearance, mainly by hepatic macrophages.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paroxysmal cold hemoglobinuria (PCH)</strong> – PCH is an AIHA seen almost exclusively in children, most commonly after a viral-like illness. PCH is characterized by IgG autoantibodies targeting the P antigen that bind preferentially at colder temperatures; fix complement efficiently; and cause intravascular hemolysis with hemoglobinemia, hemoglobinuria, and anemia. PCH is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria"</a>.)</p><p></p><p class="headingAnchor" id="H2949579851"><span class="h2">Primary versus secondary AIHA</span><span class="headingEndMark"> — </span>AIHA is classified as either primary (idiopathic) or secondary based on whether or not an underlying disease process is present  (<a class="graphic graphic_table graphicRef57399" href="/d/graphic/57399.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H3662331634"><span class="h3">Primary AIHA</span><span class="headingEndMark"> — </span>In primary AIHA (also called idiopathic AIHA), red blood cell (RBC) autoantibodies are present and cause hemolytic anemia, but no evidence of an underlying systemic illness exists. Primary AIHA accounts for approximately 40 to 50 percent of pediatric AIHA cases; most are due to warm-reactive autoantibodies [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H2531293655"><span class="h3">Secondary AIHA</span><span class="headingEndMark"> — </span>AIHA occurring in association with another systemic illness is referred to as secondary AIHA  (<a class="graphic graphic_table graphicRef57399" href="/d/graphic/57399.html" rel="external">table 2</a>). Secondary AIHA is most commonly due to warm-reactive autoantibodies, with the exception of postinfectious cases, which are typically caused by cold agglutinins. More than one-half of all cases of pediatric AIHA are secondary, and, therefore, the possibility of an underlying systemic illness should be considered in all children presenting with AIHA [<a href="#rid3">3</a>]. (See <a class="local">'Evaluation for secondary causes'</a> below.)</p><p class="headingAnchor" id="H2106912262"><span class="h4">Autoimmune disease</span><span class="headingEndMark"> — </span>Systemic autoimmune diseases are common secondary causes of AIHA, particularly in adolescents [<a href="#rid4">4</a>]. Autoimmune or inflammatory disorders that have been reported to be associated with AIHA include [<a href="#rid3">3,5,6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus (see  <a class="medical medical_review" href="/d/html/98076.html" rel="external">"Systemic lupus erythematosus (SLE) in children: Treatment, complications, and prognosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sjögren's disease (see  <a class="medical medical_review" href="/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease", section on 'Hematologic manifestations'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scleroderma (see  <a class="medical medical_review" href="/d/html/6422.html" rel="external">"Juvenile systemic sclerosis (scleroderma): Classification, clinical manifestations, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Juvenile idiopathic arthritis (see  <a class="medical medical_review" href="/d/html/6413.html" rel="external">"Systemic juvenile idiopathic arthritis: Clinical manifestations and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dermatomyositis (see  <a class="medical medical_review" href="/d/html/6419.html" rel="external">"Juvenile dermatomyositis and other idiopathic inflammatory myopathies: Epidemiology, pathogenesis, and clinical manifestations"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitiligo (see  <a class="medical medical_review" href="/d/html/105109.html" rel="external">"Vitiligo: Pathogenesis, clinical features, and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ulcerative colitis (see  <a class="medical medical_review" href="/d/html/5879.html" rel="external">"Clinical presentation and diagnosis of inflammatory bowel disease in children"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune hepatitis (see  <a class="medical medical_review" href="/d/html/3665.html" rel="external">"Overview of autoimmune hepatitis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Type 1 diabetes mellitus (see  <a class="medical medical_review" href="/d/html/5816.html" rel="external">"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune thyroiditis (see  <a class="medical medical_review" href="/d/html/5838.html" rel="external">"Acquired hypothyroidism in childhood and adolescence", section on 'Autoimmune thyroiditis'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoimmune lymphoproliferative syndrome (ALPS) (see  <a class="medical medical_review" href="/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis"</a>)</p><p></p><p>Children with these disorders probably have a genetic susceptibility to immune dysregulation, which leads to the expansion and proliferation of autoreactive B lymphocytes. There may be a family history of autoimmune disorders. It should be noted that in some of these disorders (eg, systemic lupus erythematosus), the direct antiglobulin test (DAT) may be weakly positive without clinical or laboratory evidence of hemolysis, and such patients are not considered to have AIHA.</p><p class="headingAnchor" id="H683176003"><span class="h4">Immunodeficiency</span><span class="headingEndMark"> — </span>Children with primary immunodeficiency may develop secondary AIHA, almost certainly caused by altered immune regulation [<a href="#rid7">7</a>]. AIHA can present in children as the initial manifestation of an unsuspected congenital immunodeficiency disorder, particularly common variable immunodeficiency (CVID) and Wiskott-Aldrich syndrome. (See  <a class="medical medical_review" href="/d/html/16132.html" rel="external">"Common variable immunodeficiency in children", section on 'Autoimmune disease'</a> and  <a class="medical medical_review" href="/d/html/3953.html" rel="external">"Wiskott-Aldrich syndrome", section on 'Autoimmune manifestations'</a>.)</p><p>Children with acquired immunodeficiency, including those infected with HIV, can develop erythrocyte autoantibodies and secondary AIHA caused by polyclonal B lymphocyte activation and poor immune regulation by T lymphocytes. (See  <a class="medical medical_review" href="/d/html/6679.html" rel="external">"HIV-associated cytopenias", section on 'Anemia'</a>.)</p><p class="headingAnchor" id="H1240371330"><span class="h4">Evans syndrome</span><span class="headingEndMark"> — </span>Evans syndrome is characterized by AIHA, immune thrombocytopenia (ITP), and/or autoimmune neutropenia. Some patients present with isolated AIHA and then develop additional cytopenias months or even years after the initial clinical presentation. Other patients develop ITP initially and subsequently develop AIHA. Evans syndrome accounts for approximately 15 to 30 percent of pediatric AIHA [<a href="#rid1">1,2</a>]. Compared with AIHA presenting alone, Evans syndrome is more difficult to treat and tends to have a clinical course that is chronic and relapsing [<a href="#rid8">8,9</a>]. These patients are also more likely to have or develop systemic autoimmunity. (See  <a class="medical medical_review" href="/d/html/107301.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome"</a>.)</p><p>A variety of immunoregulatory abnormalities in Evans syndrome have been described [<a href="#rid10">10-12</a>], with additional novel defects being identified as more detailed testing is being performed. Autoantibodies apparently are directed against specific antigens on each of the various blood cell types, without cross-reactivity [<a href="#rid13">13</a>].</p><p>A substantial proportion of children who present with Evans syndrome have ALPS as the underlying etiology of their immune dysregulation [<a href="#rid14">14,15</a>]. For this reason, all children who present with AIHA and another cytopenia should be screened for ALPS. In one study of 45 children with Evans syndrome, nearly one-half were found to have ALPS [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis"</a>.)</p><p>If the ALPS evaluation is negative, other disorders should be considered, including CVID and gene variants that can be associated with AIHA (eg, <em>CTLA4</em>, <em>LRBA</em>, and gain-of-function mutations in <em>STAT3</em>); targeted treatments are available for some of these [<a href="#rid11">11,12,16</a>]. Primary immunodeficiency genetic panels are available to evaluate for these disorders. (See  <a class="medical medical_review" href="/d/html/16132.html" rel="external">"Common variable immunodeficiency in children", section on 'Autoimmune disease'</a>.)</p><p class="headingAnchor" id="H2965769796"><span class="h4">Malignancy</span><span class="headingEndMark"> — </span>Secondary AIHA can occur in the setting of malignancy, occasionally presenting <strong>before</strong> the underlying diagnosis has been made. AIHA can occur in children with Hodgkin lymphoma, acute leukemia, or myelodysplasia [<a href="#rid17">17,18</a>]. It can also occur following hematopoietic stem cell transplantation. (See <a class="local">'Transplantation'</a> below.)</p><p>The pathogenesis of the erythrocyte autoantibodies in association with malignancy is unknown, but an underlying immune deficiency may lead to both autoimmune phenomena and malignancy.</p><p>Malignancy can present during or even after the episode of hemolytic anemia has occurred, particularly for children with AIHA secondary to an underlying immune deficiency such as CVID or ALPS. (See  <a class="medical medical_review" href="/d/html/7140.html" rel="external">"Causes of anemia in patients with cancer"</a>.)</p><p class="headingAnchor" id="H572868065"><span class="h4">Infection</span><span class="headingEndMark"> — </span>Infection is another important cause of AIHA. Specific infectious agents that may trigger AIHA include <em>M</em>. <em>pneumoniae</em> [<a href="#rid19">19</a>], Epstein-Barr virus [<a href="#rid20">20,21</a>], severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [<a href="#rid22">22,23</a>], measles, varicella, adenovirus, mumps, and rubella [<a href="#rid6">6</a>]. Most of these infections are associated with cold agglutinins due to IgM autoantibodies with a specificity for the I/i polysaccharide antigen system on red cells [<a href="#rid24">24</a>], although reactivity with the P polysaccharide antigen has been reported  (<a class="graphic graphic_table graphicRef61974" href="/d/graphic/61974.html" rel="external">table 3</a>) [<a href="#rid25">25,26</a>]. (See  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'RBC antigens'</a>.)</p><p>Most children who present with PCH have had a recent viral-like illness, though the specific pathogen often is not identified [<a href="#rid27">27,28</a>].</p><p>Acute bacterial infections such as clostridial or pneumococcal infections also can cause hemolytic anemia, but the mechanism is distinct. (See  <a class="medical medical_review" href="/d/html/7168.html" rel="external">"Non-immune (Coombs-negative) hemolytic anemias in adults", section on 'Infections (RBC parasites and intracellular bacteria)'</a>.)</p><p class="headingAnchor" id="H1238904674"><span class="h4">Transplantation</span><span class="headingEndMark"> — </span>AIHA can develop in the setting of allogeneic hematopoietic stem cell transplantation, typically in the first two to six months post-engraftment [<a href="#rid29">29-31</a>]. Patients with this complication usually do not respond well to traditional therapies, and some end fatally [<a href="#rid32">32-35</a>]. </p><p>AIHA may also occur following pediatric solid organ transplantation, sometimes in conjunction with ITP. In this setting, it remains unclear whether the etiology reflects the activity of donor lymphocytes (from transplants involving liver or small bowel with spleen) or the strong immunosuppression used to prevent organ rejection [<a href="#rid34">34,36</a>]. In two reports, the most effective therapy was changing immunosuppression from <a class="drug drug_pediatric" data-topicid="12822" href="/d/drug information/12822.html" rel="external">tacrolimus</a> to another agent such as <a class="drug drug_pediatric" data-topicid="12761" href="/d/drug information/12761.html" rel="external">sirolimus</a> [<a href="#rid34">34,37</a>].</p><p class="headingAnchor" id="H1003787123"><span class="h4">Drugs</span><span class="headingEndMark"> — </span>Although not common in children, erythrocyte autoantibodies and hemolysis in association with drug exposure may cause secondary AIHA. This process was described classically after therapy with <a class="drug drug_pediatric" data-topicid="12597" href="/d/drug information/12597.html" rel="external">methyldopa</a>, but red cell autoantibodies have been reported in association with many different pharmaceutical agents  (<a class="graphic graphic_table graphicRef109693" href="/d/graphic/109693.html" rel="external">table 4</a>) [<a href="#rid38">38</a>]. Medications that are particularly important in causing AIHA in children include penicillins, cephalosporins, <a class="drug drug_pediatric" data-topicid="12830" href="/d/drug information/12830.html" rel="external">tetracycline</a>, <a class="drug drug_pediatric" data-topicid="13276" href="/d/drug information/13276.html" rel="external">erythromycin</a>, <a class="drug drug_pediatric" data-topicid="12730" href="/d/drug information/12730.html" rel="external">probenecid</a>, <a class="drug drug_pediatric" data-topicid="13028" href="/d/drug information/13028.html" rel="external">acetaminophen</a>, and <a class="drug drug_pediatric" data-topicid="13371" href="/d/drug information/13371.html" rel="external">ibuprofen</a>. In a review of the published literature on this subject, <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a> was identified as the most frequent etiologic agent [<a href="#rid39">39</a>].</p><p>The mechanism of drug-induced hemolytic anemia typically results from generation of autoantibodies, although the drug may be required to form a hapten or even a ternary complex with the erythrocyte [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia", section on 'Mechanisms'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>AIHA in children is relatively rare, with an estimated annual incidence of 0.8 to 1.25 cases per 100,000 children [<a href="#rid6">6,41</a>], rendering it more common than acquired aplastic anemia but less common than immune thrombocytopenia (ITP).</p><p>AIHA can affect children of any race or ethnicity and can present at any age from infancy through adolescence [<a href="#rid27">27,42,43</a>]. In a series of 265 children with AIHA, 37 percent were primary, 53 percent had an underlying immune disorder, and 10 percent were postinfectious [<a href="#rid1">1</a>]. Adolescents and young children (ie, &lt;2 years old) who present with AIHA are more likely to have an underlying systemic illness (secondary AIHA) and a more chronic course [<a href="#rid44">44-47</a>].</p><p class="headingAnchor" id="H9"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>The signs and symptoms of AIHA are nonspecific and are common to other types of hemolytic anemia. Symptoms are generally determined by the severity of hemolysis, and the clinical presentation may range from asymptomatic (patients with mild anemia) to severe and life-threatening (patients with acute profound anemia).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presenting symptoms</strong> – Most children with AIHA present with signs and symptoms referable to anemia, such as weakness, fatigue, shortness of breath, dizziness, and pallor. Signs of hemolysis are often present, including jaundice, icterus, and painless dark urine. Other nonspecific symptoms include abdominal pain or fever [<a href="#rid48">48</a>]. In a study of 26 children with warm AIHA, the most common presenting symptoms were pallor (100 percent), jaundice (59 percent), and fever (39 percent) [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent1">In most cases of AIHA, the anemia develops gradually and the child is typically well compensated from a cardiovascular standpoint [<a href="#rid6">6</a>]. Rarely, profound anemia develops acutely, resulting in a severe, life-threatening presentation. In an observational cohort study of 265 children with AIHA, 3 percent presented with collapse, coma, or acute kidney injury due to acute profound anemia [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">Patients with cold agglutinin disease may have symptoms related to the agglutination of red cells upon exposure to cold ambient temperatures. The most common manifestation of this is acrocyanosis, a dark, purple to gray discoloration of the skin on the most acral parts: fingertips, toes, nose, and ears. These changes disappear upon warming.</p><p></p><p class="bulletIndent1">Passage of painless dark urine, in colors ranging from gold to red to black, usually signifies hemoglobinuria secondary to intravascular hemolysis and is suggestive of cold-reactive AIHA such as cold agglutinin disease or paroxysmal cold hemoglobinuria (PCH). In contrast, patients with warm AIHA do not typically have hemoglobinuria unless there is a component of complement fixation. (See  <a class="medical medical_review" href="/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient history</strong> – In reviewing the medical history, it is important to ask about previous similar episodes. Patients with primary AIHA usually have a benign previous medical history. Previous blood cell counts (if obtained) are typically normal.</p><p></p><p class="bulletIndent1">The family history may reveal a history of immune disorders. In an observational study of 265 children with AIHA, a history of autoimmune disease or primary immunodeficiency in first-degree relatives was noted in 12 percent of cases [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">The review of systems should focus on any recent acute infectious illness, signs and symptoms of a potential underlying systemic illness, and concurrent medications  (<a class="graphic graphic_table graphicRef109693" href="/d/graphic/109693.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/7104.html" rel="external">"Drug-induced hemolytic anemia", section on 'Immune-mediated'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physical findings</strong> – On physical examination, the child with AIHA may be pale and jaundiced, especially apparent in the conjunctivae and palms. Often, tachycardia is present, and a systolic flow murmur may commonly be heard, reflecting a high-output anemic state. Cardiovascular compromise (congestive failure) is uncommon unless the hemoglobin concentration is &lt;5 g/dL.</p><p></p><p class="bulletIndent1">The liver and spleen may be palpable, but the presence of massive organomegaly or lymph node enlargement should prompt evaluation for other disorders (eg, malignancy [leukemia, lymphoma], infection [HIV, malaria, tuberculosis], or autoimmune lymphoproliferative syndrome [ALPS]) [<a href="#rid50">50</a>]. (See <a class="local">'Evaluation for secondary causes'</a> below.)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">INITIAL LABORATORY EVALUATION</span><span class="headingEndMark"> — </span>The initial laboratory evaluation of the child with AIHA includes all of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with red blood cell (RBC) indices and platelet count</p><p class="bulletIndent1"><span class="glyph">●</span>Reticulocyte count</p><p class="bulletIndent1"><span class="glyph">●</span>Review of the peripheral blood smear</p><p class="bulletIndent1"><span class="glyph">●</span>Direct antiglobulin test (DAT; formerly called the direct Coombs test)</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis, both dipstick and microscopic</p><p class="bulletIndent1"><span class="glyph">●</span>Serum markers of hemolysis, including indirect bilirubin, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), and either serum haptoglobin (for patients ≥18 months old) or plasma free hemoglobin</p><p class="bulletIndent1"><span class="glyph">●</span>Blood urea nitrogen and creatinine</p><p></p><p>In addition, a cold agglutinin titer should be obtained if cold agglutinin disease is suspected based upon the clinical presentation (eg, painless dark urine, <em>M</em>. <em>pneumoniae</em> infection, acrocyanosis upon exposure to cold), peripheral blood smear findings (clumped or agglutinated red cells  (<a class="graphic graphic_picture graphicRef50522" href="/d/graphic/50522.html" rel="external">picture 1</a>)), and/or DAT results.</p><p class="headingAnchor" id="H1997137663"><span class="h2">Complete blood count findings</span><span class="headingEndMark"> — </span>AIHA is characterized by anemia, which is often severe (ie, hemoglobin &lt;7 g/dL). The leukocyte count and platelet count are typically normal or elevated. Leukopenia and/or thrombocytopenia may suggest other etiologies, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow failure syndromes (eg, aplastic anemia) (see  <a class="medical medical_review" href="/d/html/5923.html" rel="external">"Treatment of acquired aplastic anemia in children and adolescents"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microangiopathic hemolytic anemia (eg, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura) (see  <a class="medical medical_review" href="/d/html/89549.html" rel="external">"Overview of hemolytic uremic syndrome in children"</a> and  <a class="medical medical_review" href="/d/html/1338.html" rel="external">"Diagnosis of immune TTP"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow involvement secondary to an active infection or infiltrative disease such as leukemia (see  <a class="medical medical_review" href="/d/html/6244.html" rel="external">"Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children"</a>)</p><p></p><p>As described above, AIHA with concurrent immune thrombocytopenia (ITP) is referred to as Evans syndrome. (See <a class="local">'Evans syndrome'</a> above.)</p><p>RBC indices (mean corpuscular volume [MCV] and red cell distribution width) can be helpful in some cases. Abnormalities of the RBC indices occasionally can be seen:</p><p class="bulletIndent1"><span class="glyph">●</span>In the presence of a cold or warm agglutinin, the red cells may pass through the automated counter in small clumps rather than one at a time, resulting in a spuriously increased MCV. Due to RBC clumping, the reported MCV will sometimes be at non-physiologic or implausible levels, such as 180 to 250 fL, or may be unreportable. Examination of the peripheral smear can determine whether this phenomenon is present  (<a class="graphic graphic_picture graphicRef50522" href="/d/graphic/50522.html" rel="external">picture 1</a>). (See <a class="local">'Peripheral blood smear'</a> below and  <a class="medical medical_review" href="/d/html/7166.html" rel="external">"Macrocytosis/Macrocytic anemia", section on 'Evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the presence of large numbers of spherocytes, the mean corpuscular hemoglobin concentration may be elevated, usually to levels &gt;36 g/dL. This finding is not specific to AIHA, however, as it also is present in patients with congenital (hereditary) spherocytosis.</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Reticulocyte count</span><span class="headingEndMark"> — </span>The absolute reticulocyte count usually is elevated from the normal value of 50 to 75 × 10<sup>3</sup>/microL and may reach values as high as 600 to 800 × 10<sup>3</sup>/microL. However, in one large series, an initial and transient reduction in reticulocyte count was encountered in up to 39 percent of children presenting with AIHA and may reflect a concomitant accelerated immune-mediated destruction of red blood precursors within the marrow, a temporary suppression of bone marrow activity secondary to infection, and/or a delayed bone marrow response to the hemolytic event [<a href="#rid1">1,51</a>]. Reticulocytopenia can occasionally persist and may suggest a more severe clinical course [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Peripheral blood smear</span><span class="headingEndMark"> — </span>Evaluation of the peripheral blood smear is a critical part of the patient workup in AIHA:</p><p class="bulletIndent1"><span class="glyph">●</span>In warm AIHA, numerous small spherocytes usually are present  (<a class="graphic graphic_picture graphicRef53523" href="/d/graphic/53523.html" rel="external">picture 2</a>). A few teardrop-shaped red cells or red cell fragments (schistocytes) may be present, but spherocytes should predominate. In the presence of especially severe hemolysis, RBC precursors, such as normoblasts, may be present in the circulation  (<a class="graphic graphic_picture graphicRef50601" href="/d/graphic/50601.html" rel="external">picture 3</a>). Scattered areas of RBC dimers can be seen, but large erythrocyte clumps are not common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of considerable numbers of clumped or agglutinated red cells suggests the presence of a cold-reactive AIHA  (<a class="graphic graphic_picture graphicRef50522" href="/d/graphic/50522.html" rel="external">picture 1</a>). (See  <a class="medical medical_review" href="/d/html/4435.html" rel="external">"Evaluation of the peripheral blood smear"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polychromasia, reflecting an increased number of circulating young red cells (reticulocytes), is commonly observed when an increased number of reticulocytes are released from the bone marrow to compensate for accelerated erythrocyte destruction  (<a class="graphic graphic_picture graphicRef53523" href="/d/graphic/53523.html" rel="external">picture 2</a> and <a class="graphic graphic_picture graphicRef67042" href="/d/graphic/67042.html" rel="external">picture 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Howell-Jolly bodies and nucleated red cells may also be seen on the blood smear, reflecting accelerated erythropoiesis and/or a prior splenectomy for a hemolytic process  (<a class="graphic graphic_picture graphicRef60588" href="/d/graphic/60588.html" rel="external">picture 5</a>).</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Direct antiglobulin test</span><span class="headingEndMark"> — </span>The DAT establishes the diagnosis of AIHA. In the DAT, patient RBCs are washed free of adherent proteins and reacted with a polyspecific and, if positive, specific antiserum or monoclonal antibodies prepared against IgG and a fragment of the third component of complement, C3d. The test identifies the presence of antibodies and/or complement on the surface of the erythrocyte; results are scored in a semiquantitative manner, based on the amount of red cell agglutination seen in vitro.</p><p>Appropriate characterization of the erythrocyte antibodies includes determination of the isotype, presence of complement, thermal reactivity of the antibody, and binding specificity to erythrocyte antigens  (<a class="graphic graphic_table graphicRef128183" href="/d/graphic/128183.html" rel="external">table 5</a>).</p><p>When the DAT is accurately and specifically performed, most patients with warm agglutinin AIHA will exhibit a positive result with anti-IgG or both anti-IgG and anti-C3  (<a class="graphic graphic_table graphicRef128183" href="/d/graphic/128183.html" rel="external">table 5</a>). The strength of the DAT positivity is generally correlated with the severity of hemolysis. In 3 to 10 percent of childhood cases, the DAT is negative despite good clinical evidence for the presence of warm AIHA [<a href="#rid53">53</a>]. In such cases, the amount of IgG on the erythrocyte may be below the threshold for detection by standard DAT or the AIHA may be caused by another antibody such as immunoglobulin A (IgA) [<a href="#rid54">54,55</a>] or a warm-reactive IgM [<a href="#rid56">56</a>]. Cases of IgA autoantibodies and warm-reactive IgM autoantibodies require other methods for detection such as gel cards or flow cytometry, which are available only at specialized centers. Reference laboratories are able to identify a positive DAT in approximately one-half of cases of suspected warm AIHA with initially negative DAT [<a href="#rid57">57</a>]. This highlights the importance of having a high index of suspicion for AIHA. (See  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Additional testing'</a>.)</p><p>For patients with cold agglutinin-mediated AIHA, the DAT is typically positive using anti-C3 and negative with anti-IgG  (<a class="graphic graphic_table graphicRef128183" href="/d/graphic/128183.html" rel="external">table 5</a>). When this occurs, the child's serum should be tested for cold-reactive IgG Donath-Landsteiner autoantibodies characteristic of paroxysmal cold hemoglobinuria (PCH). The details of Donath-Landsteiner antibody testing are provided in a separate topic review.</p><p class="headingAnchor" id="H3105058058"><span class="h2">Cold agglutinin titer</span><span class="headingEndMark"> — </span>The titer of cold agglutinins in the serum is the highest dilution of the serum sample at which agglutination of red cells in the cold is still seen. Cold agglutinins are present in virtually all normal individuals in low titer (less than 1 in 40). Patients with postinfectious cold agglutinin disease (which is the most common cause of cold agglutinins in children) typically have titers higher than 1 in 256 [<a href="#rid6">6</a>]. In contrast, the titers in adults with cold agglutinin disease associated with lymphoma are much higher (typically higher than 1 in 2000). Hemolysis is generally mild if the titer is less than 1 in 512. (See  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'Antibody titer and thermal amplitude'</a>.)</p><p class="headingAnchor" id="H2451660841"><span class="h2">Urinalysis and kidney function tests</span><span class="headingEndMark"> — </span>Urinalysis is performed to assess for hemoglobinuria. In addition, blood urea nitrogen and creatinine should be obtained as part of the initial evaluation because hemolysis can cause renal insufficiency.</p><p>In patients with intravascular hemolysis, hemoglobin is released into the plasma and then cleared through the kidneys into the urine. When hemoglobinuria is present, urine dipstick testing will identify the presence of blood, but microscopic examination will reveal no intact RBCs. Chronic hemoglobinuria will lead to hemosiderin accumulation in uroepithelial cells, which can be detected as a positive iron stain of cells in the urinary sediment. In contrast, the urinalysis is usually normal in patients with extravascular hemolysis (warm-reactive AIHA).</p><p class="headingAnchor" id="H18"><span class="h2">Serum markers of hemolysis</span><span class="headingEndMark"> — </span>Abnormalities of serum markers of hemolysis can be helpful in establishing the presence of a hemolytic anemia; however, these tests are not specific for AIHA and are also abnormal in other hemolytic anemias. (See  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bilirubin</strong> – Total bilirubin is elevated in most patients with AIHA because of accelerated erythrocyte destruction; it should primarily be in the unconjugated (indirect) form. Elevated direct (conjugated) bilirubin suggests the presence of intrinsic liver disease. (See  <a class="medical medical_review" href="/d/html/3615.html" rel="external">"Classification and causes of jaundice or asymptomatic hyperbilirubinemia", section on 'Disorders associated with conjugated hyperbilirubinemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>LDH, AST, and ALT</strong> – Elevated serum concentrations of LDH and AST are seen in AIHA, reflecting the presence of hemolysis, especially intravascular hemolysis. ALT and other hepatic enzymes should not be elevated in AIHA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Haptoglobin and plasma free hemoglobin</strong> – Serum haptoglobin, which binds free plasma hemoglobin, will be low to absent in most cases of AIHA. However, haptoglobin is not synthesized well in young infants; it also is an acute phase reactant, and its concentration may be elevated in the presence of infection or inflammation [<a href="#rid58">58</a>]. For these reasons, we suggest not routinely measuring the haptoglobin level as part of the evaluation in patients &lt;18 months old. Plasma free hemoglobin can be an alternative measure in these scenarios.</p><p></p><p class="headingAnchor" id="H1078101722"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of AIHA is established based on laboratory evidence of hemolysis (anemia with elevated lactate dehydrogenase [LDH] and indirect bilirubin) and positive direct antiglobulin test (DAT). The degree of anemia and the reticulocyte response are variable. Diagnostic criteria for the warm and cold AIHA are provided below. The diagnosis of paroxysmal cold hemoglobinuria (PCH) is discussed separately. (See  <a class="medical medical_review" href="/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H4015699034"><span class="h2">Warm AIHA</span><span class="headingEndMark"> — </span>The diagnosis of warm-reactive AIHA is made when <strong>both</strong> of the following are present:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic anemia (anemia, high indirect bilirubin, high LDH, low haptoglobin, and/or elevated plasma free hemoglobin)</p><p class="bulletIndent1"><span class="glyph">●</span>DAT positive for IgG; complement may or may not also be present on red cells  (<a class="graphic graphic_table graphicRef128183" href="/d/graphic/128183.html" rel="external">table 5</a>)</p><p></p><p>Spherocytes on the peripheral blood smear  (<a class="graphic graphic_picture graphicRef53523" href="/d/graphic/53523.html" rel="external">picture 2</a>) with reticulocytosis and elevated mean corpuscular hemoglobin concentration are supportive findings but are not required to establish the diagnosis.</p><p class="headingAnchor" id="H3357206764"><span class="h2">Cold AIHA</span><span class="headingEndMark"> — </span>The diagnosis of cold AIHA is made when <strong>both</strong> of the following are present:</p><p class="bulletIndent1"><span class="glyph">●</span>Hemolytic anemia (anemia, high indirect bilirubin, high LDH, low haptoglobin, and/or elevated plasma free hemoglobin)</p><p class="bulletIndent1"><span class="glyph">●</span>DAT positive for bound complement and negative for bound IgG  (<a class="graphic graphic_table graphicRef128183" href="/d/graphic/128183.html" rel="external">table 5</a>)</p><p></p><p>Red cell clumping on the peripheral blood smear  (<a class="graphic graphic_picture graphicRef50522" href="/d/graphic/50522.html" rel="external">picture 1</a>) and a high cold agglutinin titer are supportive findings but are not required to establish the diagnosis.</p><p class="headingAnchor" id="H1995910128"><span class="h2">Paroxysmal cold hemoglobinuria</span><span class="headingEndMark"> — </span>The diagnosis of PCH is discussed separately. (See  <a class="medical medical_review" href="/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H125984136"><span class="h1">FURTHER EVALUATION</span><span class="headingEndMark"> — </span>Once the diagnosis of AIHA is made, further testing is performed to evaluate for possible secondary causes and to characterize the AIHA.</p><p class="headingAnchor" id="H3713748489"><span class="h2">Evaluation for secondary causes</span><span class="headingEndMark"> — </span>All children with newly diagnosed AIHA should, at a minimum, have screening performed to evaluate for secondary causes, which are present in more than one-half of cases [<a href="#rid6">6</a>]. These evaluations should generally be performed at the time of initial diagnosis prior to initiating treatment. However, the evaluation should be deferred in children who present with severe life-threatening anemia in whom urgent treatment is warranted. (See  <a class="medical medical_review" href="/d/html/107301.html" rel="external">"Autoimmune hemolytic anemia (AIHA) in children: Treatment and outcome", section on 'Severe or life-threatening anemia'</a>.)</p><p>Our suggested initial screening tests for secondary causes of AIHA are provided below. Additional tests may be warranted based on signs, symptoms, family history, and index of suspicion. If any abnormalities are detected on the initial screening tests, further evaluation should be performed to confirm the diagnosis of the suspected secondary condition since, in some cases, the underlying illness may alter the management or prognosis.</p><p>Children who have a negative evaluation for secondary causes and are diagnosed with primary (idiopathic) AIHA should be rescreened yearly because, in many instances, the secondary disease process does not become apparent until after AIHA is diagnosed.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>All children diagnosed with AIHA</strong> – We suggest the following evaluation for secondary causes in all pediatric patients with AIHA [<a href="#rid1">1,50</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antinuclear antibody with reflex to specific antibodies if positive</p><p class="bulletIndent2"><span class="glyph">•</span>Quantitative immunoglobulins</p><p class="bulletIndent2"><span class="glyph">•</span>Serologic tests for <em>M</em>. <em>pneumoniae</em> and Epstein-Barr virus (for patients with cold AIHA only)</p><p class="bulletIndent2"><span class="glyph">•</span>Review of the patient's medications for potential drugs that may induce AIHA  (<a class="graphic graphic_table graphicRef109693" href="/d/graphic/109693.html" rel="external">table 4</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with concerning findings</strong> – Additional evaluation may be warranted for patients with unusual characteristics in the medical history, physical examination, or laboratory studies that suggest an underlying malignancy, immunodeficiency, or broader autoimmune disorder. Concerning findings that may suggest an underlying systemic disorder include history of recurrent infections, family history of immunodeficiency or autoimmune disorder, other cytopenias (neutropenia and/or thrombocytopenia), lymphadenopathy, and/or organomegaly. For these patients, additional evaluation may include the following tests:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bone marrow aspiration and biopsy – Evaluation of the bone marrow is not routinely necessary to establish the diagnosis of AIHA; however, if there are concerning clinical features, bone marrow aspiration can help exclude a malignant process, myelodysplasia, marrow infiltration with an infectious agent, or one of the bone marrow failure syndromes. In primary AIHA, the marrow aspirate usually reveals intense erythroid hyperplasia  (<a class="graphic graphic_picture graphicRef75057" href="/d/graphic/75057.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef68933" href="/d/graphic/68933.html" rel="external">picture 7</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Chest radiograph, abdominal sonography, or computed tomography scan if indicated based on the clinical findings. (See  <a class="medical medical_review" href="/d/html/6243.html" rel="external">"Overview of common presenting signs and symptoms of childhood cancer", section on 'Lymphadenopathy'</a> and  <a class="medical medical_review" href="/d/html/6243.html" rel="external">"Overview of common presenting signs and symptoms of childhood cancer", section on 'Mediastinal masses'</a> and  <a class="medical medical_review" href="/d/html/6243.html" rel="external">"Overview of common presenting signs and symptoms of childhood cancer", section on 'Abdominal masses'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for autoimmune lymphoproliferative syndrome (ALPS) by flow cytometry. (See  <a class="medical medical_review" href="/d/html/16837.html" rel="external">"Autoimmune lymphoproliferative syndrome (ALPS): Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lymphocyte subpopulations. (See  <a class="medical medical_review" href="/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HIV testing. (See  <a class="medical medical_review" href="/d/html/6006.html" rel="external">"Diagnostic testing for HIV infection in infants and children younger than 18 months"</a> and  <a class="medical medical_review" href="/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Screening for systemic lupus erythematosus with anti-double-stranded DNA antibody, complement component 3 (C3), and complement component 4 (C4). (See  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis", section on 'Laboratory findings'</a>.)</p><p></p><p class="headingAnchor" id="H1691255303"><span class="h2">Antigenic reactivity</span><span class="headingEndMark"> — </span>Determination of the antigenic specificity of erythrocyte autoantibodies is important for two reasons. First, an autoantibody with a "panreactive" pattern (which is the most common finding) will bind all cells, rendering the identification of fully compatible blood for transfusion essentially impossible. Second, identification of the antigenic specificity also can help predict intravascular lysis caused by complement activation. If the antigen is within the Rhesus (Rh) complex, complement-mediated intravascular hemolysis is unlikely. The P antigen system, in contrast, is capable of binding sufficient IgG antibody to allow Donath-Landsteiner antibodies (IgG antibodies that react with the red cell at reduced temperature but not at 37°C) to fix complement completely and allow intravascular lysis [<a href="#rid59">59</a>]. (See  <a class="medical medical_review" href="/d/html/7084.html" rel="external">"Cold agglutinin disease", section on 'RBC antigens'</a> and  <a class="medical medical_review" href="/d/html/7078.html" rel="external">"Warm autoimmune hemolytic anemia (AIHA) in adults", section on 'Antibody and antigen characteristics'</a>.)</p><p class="headingAnchor" id="H4253133871"><span class="h2">Presence of alloantibodies</span><span class="headingEndMark"> — </span>Patients with AIHA who have been exposed to foreign red blood cells (RBCs) by previous transfusion or pregnancy should be tested for the presence of coexisting alloantibodies by performing an antibody screen on the patient's plasma. If alloantibodies are detected, extended blood phenotyping or genotyping is warranted to help find compatible blood. Alloantibodies may cause major transfusion reactions in such patients if not discovered. (See  <a class="medical medical_review" href="/d/html/7954.html" rel="external">"Red blood cell (RBC) transfusion in individuals with serologic complexity", section on 'Alloantibodies'</a>.)</p><p class="headingAnchor" id="H2261445"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis includes nonimmune causes of hemolytic anemia and other causes of jaundice and dark urine.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other hemolytic anemias</strong> – Children who present with AIHA usually have clinical, physical, and laboratory evidence of hemolytic anemia (anemia with jaundice, elevated lactate dehydrogenase [LDH], and indirect bilirubinemia). The main differential diagnosis includes causes of nonimmune hemolytic anemia, such as hemoglobinopathies, intrinsic red cell membrane or enzyme defects, and extrinsic causes of hemolysis  (<a class="graphic graphic_table graphicRef64454" href="/d/graphic/64454.html" rel="external">table 6</a>). The direct antiglobulin test (DAT) differentiates AIHA from other causes of hemolytic anemia. (See  <a class="medical medical_review" href="/d/html/5932.html" rel="external">"Overview of hemolytic anemias in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Jaundice</strong> – The child who presents with icterus and jaundice should be evaluated for the presence of underlying liver disease and Gilbert syndrome, which is a benign condition associated with unconjugated hyperbilirubinemia. Measurement of transaminases and coagulation factors can be useful in assessing hepatic function. In hemolytic anemia, the indirect (unconjugated) bilirubin fraction is typically elevated. In contrast, an elevated direct (conjugated) bilirubin level suggests the presence of intrinsic liver disease. (See  <a class="medical medical_review" href="/d/html/3615.html" rel="external">"Classification and causes of jaundice or asymptomatic hyperbilirubinemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dark urine</strong> – Patients with AIHA often present with dark urine caused by intravascular hemolysis and hemoglobinuria. Other causes of dark urine include concentrated urine, bilirubin or porphyrin precursors in the urine, hematuria, and myoglobinuria. Hemoglobinuria can be distinguished from most of these on the basis of the urinalysis (in patients with hemoglobinuria, the dipstick test is positive for blood and protein, but the microscopic analysis does not reveal intact red blood cells [RBCs]). Myoglobinuria produces similar urinalysis findings and can be distinguished from hemoglobinemia on the basis of the serum haptoglobin level, which is typically normal in the absence of hemolysis. (See  <a class="medical medical_review" href="/d/html/7196.html" rel="external">"Urinalysis in the diagnosis of kidney disease", section on 'Urine color'</a> and  <a class="medical medical_review" href="/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis", section on 'Urine findings and myoglobinuria'</a>.)</p><p></p><p class="headingAnchor" id="H2591110785"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83062.html" rel="external">"Patient education: Autoimmune hemolytic anemia (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H46"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Autoimmune hemolytic anemia (AIHA) is a collection of disorders characterized by the presence of autoantibodies that bind to the patient's own erythrocytes, leading to premature red cell destruction (hemolysis) and, when the rate of hemolysis exceeds the ability of the bone marrow to replace the destroyed red cells, to anemia and its attendant signs and symptoms. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification</strong> – AIHA is generally categorized as "warm" or "cold" based on the thermal reactivity of the autoantibodies  (<a class="graphic graphic_table graphicRef55710" href="/d/graphic/55710.html" rel="external">table 1</a>) and is classified as primary (idiopathic) or secondary based on whether or not an underlying disease process is present  (<a class="graphic graphic_table graphicRef57399" href="/d/graphic/57399.html" rel="external">table 2</a>). Common secondary causes of AIHA in children include autoimmune disease (eg, systemic lupus erythematosus), immunodeficiency, Evans syndrome, malignancy, infection, transplantation, and drugs. (See <a class="local">'Classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation</strong> – Most children with AIHA present with signs and symptoms referable to anemia, including weakness, shortness of breath, dizziness, pallor, jaundice, and/or dark urine. Cardiovascular compromise is uncommon unless the hemoglobin concentration is &lt;5 g/dL. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial laboratory evaluation</strong> – The initial laboratory evaluation of the child with AIHA includes all of the following (see <a class="local">'Initial laboratory evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Complete blood count with red blood cell (RBC) indices and platelet count</p><p class="bulletIndent2"><span class="glyph">•</span>Reticulocyte count</p><p class="bulletIndent2"><span class="glyph">•</span>Review of the peripheral blood smear</p><p class="bulletIndent2"><span class="glyph">•</span>Direct antiglobulin test (DAT; previously called the direct Coombs test)</p><p class="bulletIndent2"><span class="glyph">•</span>Urinalysis and kidney function tests (blood urea nitrogen and creatinine)</p><p class="bulletIndent2"><span class="glyph">•</span>Serum markers of hemolysis, including indirect bilirubin, lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and either serum haptoglobin (for patients ≥18 months old) or plasma free hemoglobin</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis of AIHA</strong> – The diagnosis of AIHA is established based on laboratory evidence of hemolysis (anemia with elevated LDH and indirect bilirubin) and positive DAT (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of warm-reactive AIHA is made if <strong>both</strong> of the following are present:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hemolytic anemia (anemia, high indirect bilirubin, high LDH, low haptoglobin)</p><p class="bulletIndent3"><span class="glyph">-</span>DAT positive for immunoglobulin G (IgG); complement may or may not also be present on red cells  (<a class="graphic graphic_table graphicRef128183" href="/d/graphic/128183.html" rel="external">table 5</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of cold AIHA is made when <strong>both</strong> of the following are present:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hemolytic anemia (anemia, high indirect bilirubin, high LDH, low haptoglobin)</p><p class="bulletIndent3"><span class="glyph">-</span>DAT positive for bound complement and negative for bound IgG  (<a class="graphic graphic_table graphicRef128183" href="/d/graphic/128183.html" rel="external">table 5</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of paroxysmal cold hemoglobinuria (PCH) is discussed separately. (See  <a class="medical medical_review" href="/d/html/7085.html" rel="external">"Paroxysmal cold hemoglobinuria", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for underlying cause</strong> – Once the diagnosis of AIHA is made, further testing is performed to evaluate for possible secondary causes and to characterize the AIHA. This includes the following (see <a class="local">'Further evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antinuclear antibody testing with reflex to specific antibodies if positive</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Quantitative immunoglobulins</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serologic testing for <em>Mycoplasma</em> <em>pneumoniae</em> and Epstein-Barr virus (in patients with cold AIHA only)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Review of the patient's medications to identify potential drugs that may induce AIHA  (<a class="graphic graphic_table graphicRef109693" href="/d/graphic/109693.html" rel="external">table 4</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Determination of the antigenic specificity of erythrocyte autoantibodies (see <a class="local">'Antigenic reactivity'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antibody screen to detect alloantibodies in patients who have been exposed to foreign RBCs by previous transfusion or pregnancy (see <a class="local">'Presence of alloantibodies'</a> above)</p><p></p><p class="bulletIndent1">Additional testing is performed in patients with concerning clinical findings (eg, history of recurrent infections, family history of autoimmune disease or immunodeficiency, other cytopenias [neutropenia and/or thrombocytopenia], lymphadenopathy, and/or organomegaly). (See <a class="local">'Evaluation for secondary causes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis of AIHA includes nonimmune causes of hemolytic anemia  (<a class="graphic graphic_table graphicRef64454" href="/d/graphic/64454.html" rel="external">table 6</a>) and other causes of jaundice (eg, liver disease) and dark urine. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="headingAnchor" id="H3617008270"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jenny Despotovic, DO, MS, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Aladjidi N, Leverger G, Leblanc T, et al. New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children. Haematologica 2011; 96:655.</a></li><li><a class="nounderline abstract_t">Vaglio S, Arista MC, Perrone MP, et al. Autoimmune hemolytic anemia in childhood: serologic features in 100 cases. Transfusion 2007; 47:50.</a></li><li><a class="nounderline abstract_t">Engelfriet CP, Overbeeke MA, von dem Borne AE. Autoimmune hemolytic anemia. Semin Hematol 1992; 29:3.</a></li><li><a class="nounderline abstract_t">Fong KY, Loizou S, Boey ML, Walport MJ. Anticardiolipin antibodies, haemolytic anaemia and thrombocytopenia in systemic lupus erythematosus. Br J Rheumatol 1992; 31:453.</a></li><li><a class="nounderline abstract_t">Boling EP, Wen J, Reveille JD, et al. Primary Sjogren's syndrome and autoimmune hemolytic anemia in sisters. A family study. Am J Med 1983; 74:1066.</a></li><li class="breakAll">Chou ST, Schreiber AD. Autoimmune hemolytic anemia. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed, Orkin SH, Fisher DE, Look T, et al (Eds), WB Saunders, 2015. p.411.</li><li><a class="nounderline abstract_t">Blanchette VS, Hallett JJ, Hemphill JM, et al. Abnormalities of the peripheral blood as a presenting feature of immunodeficiency. Am J Hematol 1978; 4:87.</a></li><li><a class="nounderline abstract_t">Pui CH, Wilimas J, Wang W. Evans syndrome in childhood. J Pediatr 1980; 97:754.</a></li><li><a class="nounderline abstract_t">Norton A, Roberts I. Management of Evans syndrome. Br J Haematol 2006; 132:125.</a></li><li><a class="nounderline abstract_t">Wang W, Herrod H, Pui CH, et al. Immunoregulatory abnormalities in Evans syndrome. Am J Hematol 1983; 15:381.</a></li><li><a class="nounderline abstract_t">Hadjadj J, Aladjidi N, Fernandes H, et al. Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. Blood 2019; 134:9.</a></li><li><a class="nounderline abstract_t">Besnard C, Levy E, Aladjidi N, et al. Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations. Clin Immunol 2018; 188:52.</a></li><li><a class="nounderline abstract_t">Pegels JG, Helmerhorst FM, van Leeuwen EF, et al. The Evans syndrome: characterization of the responsible autoantibodies. Br J Haematol 1982; 51:445.</a></li><li><a class="nounderline abstract_t">Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005; 105:2443.</a></li><li><a class="nounderline abstract_t">Seif AE, Manno CS, Sheen C, et al. Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study. Blood 2010; 115:2142.</a></li><li><a class="nounderline abstract_t">Olbrich P, Freeman AF. STAT1 and STAT3 mutations: important lessons for clinical immunologists. Expert Rev Clin Immunol 2018; 14:1029.</a></li><li><a class="nounderline abstract_t">Chu JY. Autoimmune hemolytic anemia in childhood Hodgkin's disease. Am J Pediatr Hematol Oncol 1982; 4:125.</a></li><li><a class="nounderline abstract_t">Sokol RJ, Hewitt S, Booker DJ. Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes. J Clin Pathol 1989; 42:1088.</a></li><li><a class="nounderline abstract_t">Murray HW, Masur H, Senterfit LB, Roberts RB. The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med 1975; 58:229.</a></li><li><a class="nounderline abstract_t">Rosenfield RE, Schmidt PJ, Calvo RC, McGinniss MH. Anti-i, a frequent cold agglutinin in infectious mononucleosis. Vox Sang 1965; 10:631.</a></li><li><a class="nounderline abstract_t">Rollof J, Eklund PO. Infectious mononucleosis complicated by severe immune hemolysis. Eur J Haematol 1989; 43:81.</a></li><li><a class="nounderline abstract_t">Lazarian G, Quinquenel A, Bellal M, et al. Autoimmune haemolytic anaemia associated with COVID-19 infection. Br J Haematol 2020; 190:29.</a></li><li><a class="nounderline abstract_t">Zama D, Pancaldi L, Baccelli F, et al. Autoimmune hemolytic anemia in children with COVID-19. Pediatr Blood Cancer 2022; 69:e29330.</a></li><li><a class="nounderline abstract_t">Bell CA, Zwicker H, Rosenbaum DL. Paroxysmal cold hemoglobinuria (P.C.H.) following mycoplasma infection: anti-I specificity of the biphasic hemolysin. Transfusion 1973; 13:138.</a></li><li><a class="nounderline abstract_t">Boccardi V, D'Annibali S, Di Natale G, et al. Mycoplasma pneumoniae infection complicated by paroxysmal cold hemoglobinuria with anti-P specificity of biphasic hemolysin. Blut 1977; 34:211.</a></li><li><a class="nounderline abstract_t">König AL, Schabel A, Sugg U, et al. Autoimmune hemolytic anemia caused by IgG lambda-monotypic cold agglutinins of anti-Pr specificity after rubella infection. Transfusion 2001; 41:488.</a></li><li><a class="nounderline abstract_t">Sokol RJ, Hewitt S, Stamps BK. Autoimmune haemolysis associated with Donath-Landsteiner antibodies. Acta Haematol 1982; 68:268.</a></li><li><a class="nounderline abstract_t">Göttsche B, Salama A, Mueller-Eckhardt C. Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases. Vox Sang 1990; 58:281.</a></li><li><a class="nounderline abstract_t">O'Brien TA, Eastlund T, Peters C, et al. Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases. Br J Haematol 2004; 127:67.</a></li><li><a class="nounderline abstract_t">Hillier K, Harris EM, Berbert L, et al. Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant. Pediatr Blood Cancer 2022; 69:e29410.</a></li><li><a class="nounderline abstract_t">Gabelli M, Ademokun C, Cooper N, Amrolia PI. Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting. Br J Haematol 2022; 196:45.</a></li><li><a class="nounderline abstract_t">Daikeler T, Labopin M, Ruggeri A, et al. New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. Blood 2013; 121:1059.</a></li><li><a class="nounderline abstract_t">Faraci M, Zecca M, Pillon M, et al. Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. Biol Blood Marrow Transplant 2014; 20:272.</a></li><li><a class="nounderline abstract_t">Schoettler M, Elisofon SA, Kim HB, et al. Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatr Blood Cancer 2015; 62:214.</a></li><li><a class="nounderline abstract_t">Barcellini W, Fattizzo B, Zaninoni A. Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives. J Blood Med 2019; 10:265.</a></li><li><a class="nounderline abstract_t">Koepsell SA, Grant W, Landmark JD. Autoantibodies to red blood cell antigens occur frequently with hemolysis among pediatric small bowel transplant recipients: clinical implications and management. Pediatr Transplant 2015; 19:62.</a></li><li><a class="nounderline abstract_t">Valentini RP, Imam A, Warrier I, et al. Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia. Pediatr Transplant 2006; 10:358.</a></li><li><a class="nounderline abstract_t">Petz LD. Drug-induced immune haemolytic anaemia. Clin Haematol 1980; 9:455.</a></li><li><a class="nounderline abstract_t">Garratty G, Arndt PA. Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology 2014; 30:66.</a></li><li><a class="nounderline abstract_t">Salama A, Mueller-Eckhardt C. On the mechanisms of sensitization and attachment of antibodies to RBC in drug-induced immune hemolytic anemia. Blood 1987; 69:1006.</a></li><li><a class="nounderline abstract_t">Aladjidi N, Jutand MA, Beaubois C, et al. Reliable assessment of the incidence of childhood autoimmune hemolytic anemia. Pediatr Blood Cancer 2017; 64.</a></li><li><a class="nounderline abstract_t">Habibi B, Homberg JC, Schaison G, Salmon C. Autoimmune hemolytic anemia in children. A review of 80 cases. Am J Med 1974; 56:61.</a></li><li><a class="nounderline abstract_t">Sokol RJ, Hewitt S, Stamps BK, Hitchen PA. Autoimmune haemolysis in childhood and adolescence. Acta Haematol 1984; 72:245.</a></li><li><a class="nounderline abstract_t">Zupańska B, Lawkowicz W, Górska B, et al. Autoimmune haemolytic anaemia in children. Br J Haematol 1976; 34:511.</a></li><li><a class="nounderline abstract_t">Wolach B, Heddle N, Barr RD, et al. Transient Donath-Landsteiner haemolytic anaemia. Br J Haematol 1981; 48:425.</a></li><li><a class="nounderline abstract_t">Heisel MA, Ortega JA. Factors influencing prognosis in childhood autoimmune hemolytic anemia. Am J Pediatr Hematol Oncol 1983; 5:147.</a></li><li><a class="nounderline abstract_t">Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003; 101:3857.</a></li><li><a class="nounderline abstract_t">Teachey DT, Lambert MP. Diagnosis and management of autoimmune cytopenias in childhood. Pediatr Clin North Am 2013; 60:1489.</a></li><li><a class="nounderline abstract_t">Naithani R, Agrawal N, Mahapatra M, et al. Autoimmune hemolytic anemia in children. Pediatr Hematol Oncol 2007; 24:309.</a></li><li><a class="nounderline abstract_t">Vagace JM, Bajo R, Gervasini G. Diagnostic and therapeutic challenges of primary autoimmune haemolytic anaemia in children. Arch Dis Child 2014; 99:668.</a></li><li><a class="nounderline abstract_t">Liesveld JL, Rowe JM, Lichtman MA. Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases. Blood 1987; 69:820.</a></li><li><a class="nounderline abstract_t">Fattizzo B, Zaninoni A, Nesa F, et al. Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. Am J Hematol 2015; 90:E149.</a></li><li><a class="nounderline abstract_t">Berentsen S, Barcellini W. Autoimmune Hemolytic Anemias. N Engl J Med 2021; 385:1407.</a></li><li><a class="nounderline abstract_t">Reusser P, Osterwalder B, Burri H, Speck B. Autoimmune hemolytic anemia associated with IgA--diagnostic and therapeutic aspects in a case with long-term follow-up. Acta Haematol 1987; 77:53.</a></li><li><a class="nounderline abstract_t">McGann PT, McDade J, Mortier NA, et al. IgA-mediated autoimmune hemolytic anemia in an infant. Pediatr Blood Cancer 2011; 56:837.</a></li><li><a class="nounderline abstract_t">Freedman J, Wright J, Lim FC, Garvey MB. Hemolytic warm IgM autoagglutinins in autoimmune hemolytic anemia. Transfusion 1987; 27:464.</a></li><li><a class="nounderline abstract_t">Rodberg K. DAT-Negative Autoimmune Hemolytic Anemia. Hematol Oncol Clin North Am 2022; 36:307.</a></li><li><a class="nounderline abstract_t">Javid J. Human serum haptoglobins: a brief review. Semin Hematol 1967; 4:35.</a></li><li><a class="nounderline abstract_t">Rosse WF. Fixation of the first component of complement (C'la) by human antibodies. J Clin Invest 1969; 47:2430.</a></li></ol></div><div id="topicVersionRevision">Topic 5934 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21228033" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17207229" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Autoimmune hemolytic anemia in childhood: serologic features in 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1570541" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1628167" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Anticardiolipin antibodies, haemolytic anaemia and thrombocytopenia in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859056" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Primary Sjogren's syndrome and autoimmune hemolytic anemia in sisters. A family study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859056" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Primary Sjogren's syndrome and autoimmune hemolytic anemia in sisters. A family study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/566031" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Abnormalities of the peripheral blood as a presenting feature of immunodeficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7191890" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evans syndrome in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16398647" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Management of Evans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6606357" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Immunoregulatory abnormalities in Evans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30940614" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330115" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pediatric-onset Evans syndrome: Heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7104228" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Evans syndrome: characterization of the responsible autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15542578" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20068224" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: a multi-institutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30280610" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : STAT1 and STAT3 mutations: important lessons for clinical immunologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7114395" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Autoimmune hemolytic anemia in childhood Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2584409" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/163580" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The protean manifestations of Mycoplasma pneumoniae infection in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5864820" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anti-i, a frequent cold agglutinin in infectious mononucleosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2767245" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Infectious mononucleosis complicated by severe immune hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374906" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Autoimmune haemolytic anaemia associated with COVID-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34490986" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Autoimmune hemolytic anemia in children with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4736363" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Paroxysmal cold hemoglobinuria (P.C.H.) following mycoplasma infection: anti-I specificity of the biphasic hemolysin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/843626" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mycoplasma pneumoniae infection complicated by paroxysmal cold hemoglobinuria with anti-P specificity of biphasic hemolysin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11316899" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Autoimmune hemolytic anemia caused by IgG lambda-monotypic cold agglutinins of anti-Pr specificity after rubella infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6817570" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Autoimmune haemolysis associated with Donath-Landsteiner antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2399693" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Donath-Landsteiner autoimmune hemolytic anemia in children. A study of 22 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15384979" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Autoimmune haemolytic anaemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated donor transplants for non-malignant diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34709706" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34195990" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pathogenesis, risk factors and therapeutic options for autoimmune haemolytic anaemia in the post-transplant setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247725" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24274983" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25308853" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Treatment and outcomes of immune cytopenias following solid organ transplant in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31496855" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25400072" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Autoantibodies to red blood cell antigens occur frequently with hemolysis among pediatric small bowel transplant recipients: clinical implications and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16677361" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Sirolimus rescue for tacrolimus-associated post-transplant autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6160935" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Drug-induced immune haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25247621" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3103708" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : On the mechanisms of sensitization and attachment of antibodies to RBC in drug-induced immune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28748541" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reliable assessment of the incidence of childhood autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4809573" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Autoimmune hemolytic anemia in children. A review of 80 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6438992" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Autoimmune haemolysis in childhood and adolescence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/990186" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Autoimmune haemolytic anaemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7259991" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Transient Donath-Landsteiner haemolytic anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6193721" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Factors influencing prognosis in childhood autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12531800" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24237984" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnosis and management of autoimmune cytopenias in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613874" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Autoimmune hemolytic anemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24599068" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Diagnostic and therapeutic challenges of primary autoimmune haemolytic anaemia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3814817" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Variability of the erythropoietic response in autoimmune hemolytic anemia: analysis of 109 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25963403" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34614331" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Autoimmune Hemolytic Anemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3107324" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Autoimmune hemolytic anemia associated with IgA--diagnostic and therapeutic aspects in a case with long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21370419" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : IgA-mediated autoimmune hemolytic anemia in an infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3686654" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Hemolytic warm IgM autoagglutinins in autoimmune hemolytic anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35282952" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : DAT-Negative Autoimmune Hemolytic Anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5343039" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Human serum haptoglobins: a brief review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4180276" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Fixation of the first component of complement (C'la) by human antibodies.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
